For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240522:nRSV3736Pa&default-theme=true
RNS Number : 3736P Benchmark Holdings PLC 22 May 2024
Information within this announcement is deemed by the Company to constitute
inside information under the Market Abuse Regulations (EU) No. 596/2014 and
Article 7 of the UK version of EU Regulation 596/2014 which forms part
of UK law by virtue of the European Union (Withdrawal) Act 2018.
22 May 2024
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Second Quarter and Half Year results for the six months ended 31 March 2024
Positive quarterly momentum maintained and well on track to meet full year
management's expectations
Benchmark (LSE: BMK), the aquaculture biotechnology company, announces its
unaudited interim results for the six months ended 31 March 2024 (the "Period"
or "H1 FY24"). The Company also announces its unaudited results for the three
months ended 31 March 2024 ("Q2 FY24") in compliance with the terms of its
unsecured Green bond.
Financial Highlights
· Q2 FY24 positive momentum in Genetics and Advanced Nutrition
partially offset by Health and forex headwinds
o Q2 FY24 revenues of £39.8m were 10% below Q2 FY23 (-3% CER) driven by a
strong performance in Genetics and Advanced Nutrition, offset by Health
§ Genetics revenues were £13.2m (Q2 FY23: £12.9m) up 7% CER reflecting a
solid performance in the core business and good progress in our growth
vectors, particularly Chile
§ Advanced Nutrition revenues were £21.1m (Q2 FY23: £22.6m) up 3% CER
reflecting the success of our strategy to adapt to difficult shrimp markets
§ Health revenues of £5.4m (Q2 FY23: £8.7m) were down 35% CER; focus
remains on transition to new business model for Ectosan®Vet and CleanTreat®
o 9% CER increase in Adjusted EBITDA excluding fair value movement in
biological assets to £9.9m (Q2 FY23: £9.9m)
o Adjusted EBITDA margin excluding fair value movement in biological assets
of 25% (Q2 FY23: 22%) in line with the Group's medium-term target
§ Genetics Adjusted EBITDA excluding fair value movement of £3.1m was 42%
above Q2 FY23 (+50% CER) due to higher profit from the Genetics joint venture
and higher egg revenues. The Adjusted EBITDA excluding fair value movement
margin was 24% (Q2 FY23: 17%)
§ Advanced Nutrition Adjusted EBITDA of £5.3m was down 14% (-3% CER) with
effective cost control offsetting reduced revenue. The Adjusted EBITDA margin
was 25%; (Q2 FY23: 27%)
§ Health Adjusted EBITDA of £1.6m (Q2 FY23: £2.6m) and Adjusted EBITDA
margin of 30% reflecting efforts to manage costs (Q2 FY23: 30%)
o Adjusted operating profit excluding fair value movements was £5.9m, 24%
above the prior year
o Operating profit was marginally below the prior year at £0.6m (Q2 FY23:
£0.7m)
o Increase in net operating cash inflow to £3.6m (Q2 FY23: £1.4m)
· H1 FY24 results underpinned by strong Q2 performance, supporting
positive outlook for the full year
o H1 FY24 revenues of £80.2m were 19% below a strong H1 FY23 (-12% CER)
which benefited from supply constraints in the salmon egg market
§ Genetics revenues were £28.4m (H1 FY23: £34.3m) down 11% CER reflecting a
normalised level against H1 FY23 which benefitted from supply constraints in
the salmon egg market
§ Advanced Nutrition revenues were £40.4m (H1 FY23: £45.3m), down 2% CER
representing a strong performance in challenging shrimp markets
§ Health revenues of £11.5m (H1 FY23: £19.1m) were down 37% CER; reduced
Ectosan®Vet and CleanTreat® capacity in the period as we transition to a new
business model
o Adjusted EBITDA excluding fair value movement in biological assets was
£17.3m, 23% below a strong H1 FY23 (-15% CER)
o Group operating costs in H1 FY24 were £20.4m, 14% below H1 FY23 with a
reduction across all business areas despite a high inflation environment
o Adjusted EBITDA margin excluding fair value movement in biological assets
was 22% (H1 FY23: 23%) with strong margins in Advanced Nutrition (24%) and
Genetics (23%) offset by Health (19%)
o Operating loss was £3.7m (H1 FY23: profit of £1.0m) primarily due to
lower revenues in the period offset by continued cost control
· Cash, liquidity and net debt:
o Cash of £24.1m and liquidity (cash and available facility) of £41.3m at
20 May 2024
o Net debt excluding lease liabilities of £56.8m at 31 March 2024 (31 March
2023: £44.5m,
30 September 2023: £45.6m)
H1 FY24 Operational Highlights
· Genetics - wide ranging progress
o Excellent progress in Chile with new customer wins, establishing
foundation for future growth
o Launch of a new product portfolio in salmon genetics aligned with our
strategy to invest in R&D to further enhance our customer value
proposition and our competitive position
o Successful launch of genotyping product portfolio; contracted customer
projects commenced
o Successful integration of shrimp activities with Advanced Nutrition
generating commercial opportunities while we continue the work to develop
local adapted strains
o Significant progress in key innovation areas - complex gill disease
project bolstered by a new partnership funded by the Biotechnology and
Biological Sciences Research Council in the UK
· Advanced Nutrition - well positioned for recovery
o The strategy and mitigating actions taken by management in response to
challenging shrimp markets including the continuous development of our product
portfolio, the establishment of new routes to market and the implementation of
operational efficiencies are delivering positive results
o Green shoots of recovery in the shrimp market translating into demand for
the Group's hatchery portfolio as the industry prepares to increase production
o Well positioned for market recovery
· Health - progress with development of new business model
o Further progress made towards development of new business model for
Ectosan® Vet and CleanTreat® aimed at reducing infrastructure costs.
Design of the wellboat configuration completed in partnership with
wellboat equipment provider MMC and wellboat designer SALT
o Existing infrastructure being streamlined, rightsizing it for the new
business model
o Strong sales of Salmosan® Vet reflecting successful lifecycle management
and strength of the Group's sea lice solution portfolio
Current trading and outlook
The Company is trading in line with management's expectations for the full
year. There is good visibility of revenue in Genetics including excellent
progress in Chile, and there have been no operational or financial
consequences from the infectious salmon anaemia (ISA) incident reported in
February this year. In Advanced Nutrition, there is continuing strong
performance in soft markets albeit with some green shoots and the business is
well positioned for market recovery. In Health, our focus remains on the
transition to the new business model for Ectosan® Vet and CleanTreat®. We
will continue to manage costs and reduce our capital exposure, taking the
second CleanTreat® unit out ahead of the low season for sea lice
treatments. Our established sea lice treatment Salmosan® Vet is performing
well into the second half of the year.
Strategic review
In January 2024, the Company announced that the Board had unanimously decided
to undertake a formal review of the Company's strategic options including a
potential formal sale process. This process remains ongoing and further
updates will be provided as appropriate.
Financial Summary
£m Q2 FY23 % CER % CER
Q2 FY24 Q2 FY24 H1 FY24 H1 FY23 H1 FY24
Revenue 39.8 44.2 -3% 80.2 98.7 -12%
-10% -19%
Adjusted
Adjusted EBITDA(1) 10.1 11.3 -1% 16.8 22.6 -18%
-10% -26%
Adjusted EBITDA excl. bio asset fair value movements 9.9 9.9 +9% 17.3 22.4 -15%
0% -23%
Adjusted Operating profit(2) 6.2 6.2 +15% 6.0 12.4 -40%
0% -51%
Adjusted Operating profit excl. bio asset fair value movements 5.9 4.8 +42% 6.5 12.1 -34%
+24% -46%
Statutory
Operating profit/(loss) 0.6 0.7 (3.7) 1.0
-6% -468%
Loss before tax (0.7) (1.7) (7.9) (1.2)
+61% -564%
Basic loss per share (p) (0.18) (0.40) (1.21) (0.57)
Net debt(3) (72.7) (66.3) (72.7) (66.3)
Net debt(3) excluding lease liabilities (56.8) (44.5) (56.8) (44.5)
*Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure
(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs
(3) Net debt is cash and cash equivalents less loans and borrowings
Business Area summary
£m % CER* %CER*
Q2 FY24 Q2 FY23 Q2 FY24 H1 FY24 H1 FY23 H1 FY24
Revenue
Advanced Nutrition 21.1 22.6 +3% 40.4 45.3 -2%
-7% -11%
Genetics 13.2 12.9 +7% 28.4 34.3 -11%
+2% -17%
Health 5.4 8.7 -35% 11.5 19.1 -37%
-38% -40%
Adjusted EBITDA(1)
Advanced Nutrition 5.3 6.2 -3% 9.9 11.5 -5%
-14% -14%
Adjusted EBITDA Margin (%) 25% 27% 24% 25%
Genetics 3.4 3.6 1% 5.9 6.5 -2%
-5% -10%
- Net of fair value movement in biological assets 3.1 2.2 +50% 6.4 6.3 +12%
+42% +2%
Adjusted EBITDA Margin (%) excl. fair value movements in biological assets 24% 17% 23% 18%
Health 1.6 2.6 -34% 2.2 6.6 -65%
-37% -67%
Adjusted EBITDA Margin (%) 30% 30% 19% 35%
*Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure
Trond Williksen, CEO, commented:
"I am pleased with the Company's performance in the second quarter, and the
first half as a whole, which demonstrated good momentum in the business
supporting our positive outlook. We have delivered strong trading in our
established business areas, have made excellent progress in Chile, one of our
key growth vectors, and made significant progress in our innovation programme
where our recent investment to strengthen our innovation capabilities is
bearing fruit. We remain focused on the transition to a new business model for
Ectosan® Vet and CleanTreat® which will strengthen our sea lice solutions
portfolio and deliver a much needed alternative to our customers.
"With our unique platform of mission critical specialised solutions in areas
where we hold market leading positions we are strongly positioned to continue
to deliver growth and to build sustainable shareholder value."
Presentation for analysts and institutional investors at 8.00 UK (9.00 CET)
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a presentation for analysts and institutional investors on
the day at 08.00 UK time (9.00 CET).
The presentation will be held in person at Haakon Vlls Gate 2, Oslo, Norway.
To register your interest, please contact benchmark@mhpgroup.com
(mailto:benchmark@mhpgroup.com)
A live webcast of the presentation will be available for analysts and
investors to join remotely at the following link:
https://channel.royalcast.com/landingpage/hegnarmedia/20240522_1/
(https://channel.royalcast.com/landingpage/hegnarmedia/20240522_1/)
Equity Development webcast for retail investors at 12:30pm UK time
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a second webcast for retail investors and wealth managers at
12.30pm UK time. The webcast is open to all existing and potential
shareholders.
To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-22may2024
(https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-22may2024)
Enquiries
For further information, please contact:
Benchmark Holdings plc benchmark@mphgroup.com (mailto:benchmark@mphgroup.com)
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Numis (Broker and NOMAD) Tel: +44 20 7260 1000
Freddie Barnfield, Duncan Monteith, Sher Shah
MHP Group Tel: +4420 3128 8100/ +44 7884 494112
Katie Hunt, Reg Hoare
benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)
About Benchmark
Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth, animal health and welfare.
Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses the major aquaculture species in all the
major aquaculture regions around the world. Find out more at
www.benchmarkplc.com (http://www.benchmarkplc.com)
Management Report
Q2 FY24 commentary
The Group delivered a strong performance in Q2 FY24 with Genetics and Advanced
Nutrition performing strongly against a backdrop of difficult conditions in
the shrimp markets, and progress made in Health towards a new business model
for Ectosan® Vet and CleanTreat®. Group revenue was £39.8m, 10% below a
strong Q2 FY23
(-3% CER). Adjusted EBITDA excluding fair value movement in biological
assets was £9.9m, in line with Q2 FY23 despite strong forex headwinds, and
ahead +9% at constant exchange rate. The Adjusted EBITDA margin excluding fair
value movement in biological assets of 25% was in line with the Group's
medium-term target (Q2 2023: 22%).
By business area, Genetics reported Q2 FY24 revenues of £13.2m, 2% above Q2
FY23 (+7% CER) driven by higher egg revenues (+2%) as well as higher harvest
income (+70%) and genetic services revenues (+17%), partially offset by lower
revenues in ancillary products. Adjusted EBITDA excluding fair value movements
in biological assets was £3.1m, up 42% on the prior year (Q2 FY23: £2.2m)
reflecting higher revenues as well as higher profits from the Genetics joint
venture in the period of £0.7m (Q2 FY23: nil). The Adjusted EBITDA margin
excluding fair value movements was 24% (Q2 FY23: 17%) reflecting higher profit
from the joint venture and higher harvest income. There was excellent progress
in Chile, a key growth vector for the Group with an increasing number of
customers, building our market position and achieving operational
profitability. In shrimp, the integration of our shrimp genetics commercial
activities with Advanced Nutrition to leverage our commercial capabilities is
creating new opportunities as we continue the development of local adapted
strains. Shrimp sales were £0.5m in the period 31% above the prior year.
During the period we successfully launched a new genotyping product portfolio
and there are a number of contracted customer projects already underway which
underpin future revenue. Innovation is a key component of our Genetics
strategy and significant progress was made in our key R&D projects in the
period. This included a new partnership for our complex gill disease project,
which was bolstered by a new important partnership with funding from the
Biotechnology and Biological Sciences Research Council in the UK.
Advanced Nutrition delivered Q2 FY24 revenues of £21.1m, 7% below Q2 FY23
largely due to forex impact (+3% CER) but 10% above Q1 FY24 showing good
quarterly momentum. Q2 FY24 Adjusted EBITDA was £5.3m (Q2 FY23: £6.2m) with
the impact of the lower sales partially offset by efficient cost control. The
Adjusted EBITDA margin was 25% (Q2 FY23: 27%). While the shrimp markets
remain soft, there are green shoots of recovery which translated into
improving demand for our hatchery portfolio in the period as the industry
prepares to increase production as further signs of recovery emerge.
In Health, Q2 FY24 revenues were £5.4m, 38% below Q2 FY23 (-35% CER), and
Adjusted EBITDA was £1.6m (Q2 FY23: £2.6m). Sales of Salmosan® Vet were
strong reflecting successful lifecycle management and the strength of the
Group's sea lice solution portfolio. Our focus remains on the development of
alternative operating models for Ectosan® Vet and CleanTreat® including
barge and wellboat configurations. As part of this transition we are
streamlining the infrastructure and organisation in Health, rightsizing for
the new business model which will result in cost savings. Early in the quarter
we took one of the two platform supply vessels (PSV) carrying the CleanTreat®
systems out of service and we have streamlined the rest of the organisation
accordingly. The wellboat configuration represents the long-term solution,
with the CleanTreat® systems integrated into future wellboats owned and
operated by customers or service providers. We have completed the design for
the wellboat configuration in partnership with leading wellboat equipment
provider, MMC, and leading wellboat designer SALT, and together we are now
promoting the solution as part of the offering of new wellboats in the market.
Group operating costs were £9.9m, 19% below prior year (Q2 FY23: £12.2m) as
focus continues on cost control across the Group, including streamlining the
infrastructure of the Health business area, a programme of operational
efficiencies and the ongoing integration of our activities around species.
R&D expenses of £1.5m were marginally above the prior year (Q2 FY23:
£1.4m) and represented 4% of Group revenues (Q2 FY23: 3%). Exceptional costs
in the quarter, mainly related to the ongoing strategic review, were £2.0m
(Q2 FY23: £1.7m related to costs in preparation for an Oslo listing).
Depreciation and amortisation was £7.5m (Q2 FY23: £8.9m) with the reduction
mainly relating to right of use assets in Health, leading to a Group operating
profit of £0.6m (Q2 FY23: £0.7m). Adjusted operating profit excluding fair
value movement in biological assets was £5.9m, 24% (+42% CER) ahead of the
prior year (Q2 FY23: £4.8m).
Net finance costs of £1.3m for the quarter were £1.1m lower than the same
period last year (Q2 FY23: £2.4m), mainly due to net forex gains in the
period of £1.3m (Q2 FY23: loss of £0.7m) partially offset by higher interest
costs. Loss before tax for the quarter was £0.7m (Q2 FY23: £1.7m).
The tax charge for the quarter was £0.5m (Q2 FY23: £0.7m) resulting in loss
after tax of £1.1m (Q2 FY23: £2.4m).
The Group reported a net operating cash outflow of £3.6m after an increase in
working capital of £1.9m (Q2 FY23: £3.4m) and tax payments of £2.5m (Q2
FY23: £2.6m). Net cash outflow from investing activities was £0.7m (Q2 FY23:
£1.3m) of which capex was £0.9m (Q2 FY23: £1.6m) offset by proceeds from
sale of fixed assets, the reduction comes as the significant investment
programme to support the Group's growth plans is now complete.
Net cash outflow from financing activities was £5.9m (Q2 FY23: £3.4m).
Current period relates to payments for interest and lease and borrowings
payments, whereas prior year included increase in bank borrowings of £9.2m
offset by £8.0m for acquisition of minority interest in Iceland.
Half year commentary
Revenues in H1 FY24 were £80.2m, 19% below a strong H1 FY23 (-12% CER) but
13% above the H2 FY23 period showing positive sequential progress against a
backdrop of difficult conditions in the shrimp markets. Adjusted EBITDA
excluding fair value movements from biological assets was £17.3m down 23%
(-15% CER). The Adjusted EBITDA margin excluding fair value movement was
marginally below at 22% (H1 FY23: 23%) with a higher contribution from joint
venture profit offsetting a slightly lower gross profit margin of 49% (H1
FY23: 50%).
By business area, Advanced Nutrition delivered a strong performance against
challenging markets, with green shoots of recovery in Q2 FY24. First half
revenues were £40.4m, 11% below H1 FY23 impacted by forex headwinds (-2% CER)
but 22% ahead of H2 FY23 showing sequential progression partially reflecting
signs of market improvement as mentioned above. H1 FY24 Adjusted EBITDA was
£9.9m, 14% below H1 FY23 (-5% CER) resulting in Adjusted EBTIDA margin of 24%
(H1 FY23: 25%). While conditions in the shrimp market remained difficult,
signs of recovery give us optimism and we are confident that the business is
very well positioned to benefit from market recovery, with the strategy and
mitigating actions implemented over recent periods including development of
our product portfolio and technologies, new routes to market and operational
efficiencies delivering results.
Genetics performed well against a comparatively strong H1 FY23. Revenues of
£28.4m were 17% below H1 FY23 and were impacted by adverse forex (CER -11%).
The drop in revenues was driven by a 20% reduction in salmon egg revenues
against H1 FY23, which benefitted from supply constraints in the salmon egg
market and lower revenues from ancillary products and other income, partially
offset by a 12% increase in harvest revenues and a 9% increase in revenues
from Genetic Services. Revenues from shrimp genetics were marginally down.
Adjusted EBITDA excluding fair value movement was £6.4m 2% above the prior
year (+12% CER) resulting in a lift in Adjusted EBITDA margin excluding fair
value movement to 23% (H1 FY23: 18%).
In Health, we continue our effort to transition to a new infrastructure and
business model for Ectosan® Vet and CleanTreat® including streamlining our
infrastructure and reducing capacity to manage costs during the transition
period. Revenues in H1 FY24 were £11.5m 40% below the prior year (-37% CER)
driven by a drop in Ectosan® Vet and CleanTreat® while revenues from
Salmosan® Vet were 8% down as a result of a change in geographic mix with an
increase in volume offset by lower average price.
Group operating costs in H1 FY24 were £20.4m, 14% below H1 FY23 with a
reduction across all business areas despite a high inflation environment. This
is the result of well embedded cost control across the Group, a programme of
operational efficiencies and the ongoing integration of our activities around
species. R&D expenses were £3.1m (H1 FY23: £3.0m) and total R&D
investment including capitalised development costs was £3.2m, in line with
the prior year (H1 FY23: £3.2m). Depreciation and amortisation were £18.1m
(H1 FY23: £18.9m) with the reduction mainly related to right of use assets
in the Health business area.
The Group reported an operating loss of £3.7m (H1 FY23: £1.0m profit) as a
result of lower revenues partially offset by a reduction in operating costs
and increased profit from joint ventures. Adjusted operating profit excluding
fair value movements from biological assets was £6.5m, 46% below H1 FY23
(-34% CER) but significantly ahead (+151%) of the most recent six month
period.
Net finance costs for H1 FY24 were £4.1m (H1 FY23: £2.2m). Interest costs
were higher due to higher borrowings during the current year, and the
remainder of the increase is the result of income from ineffectiveness in
hedge accounting in the prior year offset by differences in foreign exchange
gains and losses year on year.
Loss before tax in H1 FY24 was £7.9m (H1 FY23: £1.2m). This included the
impact of significant exceptional costs in the period of £2.5m (H1 FY23:
£2.7m), largely related to the ongoing strategic review and restructuring
costs associated with the integration of our shrimp genetics activities and
other operational efficiency initiatives, while those in the prior period were
primarily concerned with preparation for a listing of the Group in Oslo.
Total tax charge in H1 FY24 was £0.9m (H1 FY23: £1.5m) with a small
reduction (+£0.2m) in current tax charges in the territories for which no
loss relief is available, together with a higher deferred tax credit (+£0.4m)
from the reversal of temporary differences. Loss after tax was £8.8m (H1
FY23: £2.7m loss).
The Group reported a net operating cash outflow of £2.0m after an increase in
working capital of £12.8m (H1 FY23: £4.2m) and tax payments of £3.7m (H1
FY23: £4.1m). The increase in working capital is somewhat seasonal, but the
larger increase this year is due to higher receivables resulting from
increased harvest income and timing of egg sales in Genetics, a reduction in
payables in Advanced Nutrition due to different timing, and the utilisation of
the demobilisation provision in Health following decommissioning of one of the
vessels. Net cash outflow from investing activities was £1.5m (H1 FY23:
£3.4m) as the significant investment programme to support the Group's growth
plans is now complete. The majority of the outflow in the period relates to
maintenance capex in Genetics.
Net cash outflow from financing activities was £11.4m (H1 FY23: £1.2m).
Interest payments in the period were £4.5m (H1 FY23: £4.1m) and lease
payments were £5.4m (H1 FY23: £4.7m). Additionally, H1 FY23 included an
equity raise of (net) £11.4m, net proceeds from debt refinancing of £4.2m,
and payments to acquire the minority interests in Benchmark Genetics Iceland
of £8.0m. The cash position at 31 March 2024 was £20.8m (H1 FY23: £38.6m;
FY23: £36.5m), and net debt including lease liabilities was £72.7m (H1 FY23:
£66.3m; FY23: £65.5m).
Outlook
The Company is trading in line with management's expectations for the full
year. There is good visibility of revenue in Genetics including excellent
progress in Chile and no operational or financial consequences from the ISA
incident reported in February this year. In Advanced Nutrition there is
continuing strong performance in soft markets albeit with some green shoots,
and the business is well positioned for market recovery. In Health our focus
remains on the transition to the new business model for Ectosan® Vet and
CleanTreat®. We will continue to manage costs and reduce our capital
exposure, taking the second CleanTreat® unit out of service ahead of the low
season for sea lice treatments. Our established sea lice treatment
Salmosan® Vet is performing well into the second half of the year.
Benchmark Holdings plc
Consolidated Income Statement for the period ended 31 March 2024
All figures in £000's Notes Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
Restated*
(unaudited)
Restated*
(audited)
(unaudited)
(unaudited)
Revenue 4 39,751 44,237 80,224 98,659 169,476
Cost of sales (18,866) (19,313) (40,976) (49,337) (82,726)
Gross profit 20,885 24,924 39,248 49,322 86,750
Research and development costs (1,542) (1,434) (3,059) (2,985) (6,069)
Other operating costs (9,862) (12,203) (20,352) (23,771) (45,157)
Share of profit/(loss) of equity-accounted investees, net of tax 667 - 985 56 (32)
Adjusted EBITDA² 10,148 11,287 16,822 22,622 35,492
Exceptional - restructuring, acquisition and disposal related items 6 (1,962) (1,716) (2,479) (2,688) (3,904)
EBITDA¹ 8,186 9,571 14,343 19,934 31,588
Depreciation and impairment (3,318) (4,475) (9,567) (9,014) (18,409)
Amortisation and impairment (4,221) (4,410) (8,489) (9,912) (18,495)
Operating (loss)/profit 647 686 (3,713) 1,008 (5,316)
Finance cost 7 (3,201) (3,214) (6,497) (10,335) (15,048)
Finance income 7 1,884 791 2,349 8,143 7,670
Loss before taxation (670) (1,737) (7,861) (1,184) (12,694)
Tax on loss 8 (477) (704) (910) (1,483) (3,365)
Loss from continuing operations (1,147) (2,441) (8,771) (2,667) (16,059)
Discontinued operations
Loss from discontinued operations, net of tax 5 - (279) - (732) (5,505)
(1,147) (2,720) (8,771) (3,399) (21,564)
Loss for the year attributable to:
- Owners of the parent (1,321) (2,858) (8,948) (4,141) (23,146)
- Non-controlling interest 174 138 177 742 1,582
(1,147) (2,720) (8,771) (3,399) (21,564)
Earnings per share
Basic loss per share (pence) 9 (0.18) (0.40) (1.21) (0.57) (3.16)
Diluted loss per share (pence) 9 (0.18) (0.40) (1.21) (0.57) (3.16)
Earnings per share - continuing operations
Basic loss per share (pence) 9 (0.18) (0.36) (1.21) (0.47) (2.41)
Diluted loss per share (pence) 9 (0.18) (0.36) (1.21) (0.47) (2.41)
Adjusted EBITDA from continuing operations 10,148 11,287 16,822 22,622 35,492
Adjusted EBITDA from discontinued operations 5 - (194) - (562) (1,254)
Total Adjusted EBITDA 10,148 11,093 16,822 22,060 34,238
1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment
2 Adjusted EBITDA - EBITDA before exceptional items including acquisition
related items
* Q2 2023 numbers have been restated to reflect certain operations of the
Group that have been classified as discontinued operations during the
period in line with IFRS 5. (See Note 5).
Benchmark Holdings plc
Consolidated Statement of Comprehensive Income for the period ended 31 March
2024
All figures in £000's Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Loss for the period (1,147) (2,720) (8,771) (3,399) (21,564)
Other comprehensive income
Items that are or may be reclassified subsequently to profit or loss
Foreign exchange translation differences (3,579) (5,973) (10,992) (24,013) (23,475)
Cash flow hedges - changes in fair value (1,455) 217 (2,345) (299) (2,123)
Cash flow hedges - reclassified to profit or loss 1,494 (179) 1,614 (292) 2,623
Total comprehensive income for the period (4,687) (8,655) (20,494) (28,003) (44,539)
Total comprehensive income for the period attributable to:
- Owners of the parent (4,596) (8,295) (20,337) (28,046) (45,404)
- Non-controlling interest (92) (360) (158) 43 865
(4,688) (8,655) (20,495) (28,003) (44,539)
Total comprehensive income for the period attributable to owners of the
parent:
- Continuing operations (4,596) (7,954) (20,337) (27,048) (39,777)
- Discontinued operations* - (341) - (998) (5,627)
(4,596) (8,295) (20,337) (28,046) (45,404)
* Total comprehensive income for the period relating to discontinued
operations for Q2 2024 includes the loss of £nil (Q2 2023: £279,000) and
foreign exchange loss of £nil (Q2 2023: £62,000). FY23 includes the loss of
£5,505,000 and foreign exchange loss of £122,000.
The accompanying notes are an integral part of this consolidated financial
information.
Benchmark Holdings plc
Consolidated Balance Sheet as at 31 March 2024
31 March 2024 31 March 2023 30 September 2023
All figures in £000's Notes (unaudited) (unaudited) (audited)
Assets
Property, plant and equipment 68,525 76,414 73,411
Right-of-use assets 16,717 22,365 19,804
Intangible assets 190,861 215,077 206,077
Equity-accounted investees 4,538 3,136 3,558
Other investments 1 14 14
Biological and agricultural assets 18,547 20,605 18,406
Non-current assets 299,189 337,611 321,270
Inventories 22,790 27,129 25,269
Biological and agricultural assets 25,132 22,550 27,586
Trade and other receivables 54,589 48,433 59,795
Cash and cash equivalents 20,759 38,647 36,525
123,270 136,759 149,175
Assets held for sale 10 - - 850
Current assets 123,270 136,759 150,025
Total assets 422,459 474,370 471,295
Liabilities
Trade and other payables (30,326) (29,723) (47,329)
Loans and borrowings 11 (17,292) (22,115) (20,045)
Corporation tax liability (4,583) 8,413 (6,422)
Provisions (1,843) (1,574) (1,280)
Current liabilities (54,044) (61,825) (75,076)
Loans and borrowings 11 (76,212) (82,878) (81,954)
Other payables (7,986) (6,257) (6,842)
Deferred tax (21,291) (24,293) (24,106)
Provisions - - (700)
Non-current liabilities (105,489) (113,428) (113,602)
Total liabilities (159,533) (175,253) (188,678)
Net assets 262,926 299,117 282,617
Issued capital and reserves attributable to owners of the parent
Share capital 12 739 739 739
Additional paid-in share capital 12 37,428 37,924 37,428
Capital redemption reserve 5 5 5
Retained earnings 175,344 201,962 183,489
Hedging reserve (934) (1,294) (203)
Foreign exchange reserve 44,290 54,391 54,947
Equity attributable to owners of the parent 256,872 293,727 276,405
Non-controlling interest 6,054 5,390 6,212
Total equity and reserves 262,926 299,117 282,617
The accompanying notes are an integral part of this consolidated financial
information.
Benchmark Holdings plc
Consolidated Statement of Changes in Equity for the period ended 31 March 2024
Share Additional paid-in share capital Other Hedging Retained Total attributable Non- Total
capital
reserves*
reserve
earnings
to equity holders of
controlling
equity
parent
interest
£000 £000 £000 £000 £000 £000 £000 £000
As at 1 October 2023 (audited) 739 37,428 54,952 (203) 183,489 276,405 6,212 282,617
Comprehensive income/(loss) for the period
Profit/(loss) for the period - - - - (8,949) (8,949) 177 (8,772)
Other comprehensive income/(loss) - - (10,657) (731) - (11,388) (335) (11,723)
Total comprehensive income/(loss) for the period - - (10,657) (731) (8,949) (20,337) (158) (20,495)
Contributions by and distributions to owners
Share-based payment - - - - 804 804 - 804
Total contributions by and distributions to owners - - - - 804 804 - 804
Total changes in ownership interests - - - - - - - -
Total transactions with owners of the Company - - - - 804 804 - 804
As at 31 March 2024 (unaudited) 739 37,428 44,295 (934) 175,344 256,872 6,054 262,926
As at 1 October 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
Comprehensive income/(loss) for the period
Profit/(loss) for the period - - - - (4,141) (4,141) 742 (3,399)
Other comprehensive income/(loss) - - (23,314) (591) - (23,905) (699) (24,604)
Total comprehensive income/(loss) for the period - - (23,314) (591) (4,141) (28,046) 43 (28,003)
Contributions by and distributions to owners
Share issue 35 12,985 - - - 13,020 - 13,020
Share issue costs recognised through equity - (1,386) - - - (1,386) - (1,386)
Cancellation of part of share premium account - (394,235) - - 394,235 - - -
Share-based payment - - - - 475 475 - 475
Total contributions by and distributions to owners 35 (382,900) - - 394,710 11,845 - 11,845
Changes in ownership
Acquisition of NCI - (3,470) (3,470) (4,539) (8,009)
Total changes in ownership interests - - - - (3,470) (3,470) (4,539) (8,009)
Total transactions with owners of the Company 35 (382,900) - - 391,240 8,375 (4,539) 3,836
As at 31 March 2023 (unaudited) 739 37,924 54,396 (1,294) 201,963 293,728 5,390 299,118
As at 1 October 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
Comprehensive income/(loss) for the period
Profit/(loss) for the period - - - - (23,146) (23,146) 1,582 (21,564)
Other comprehensive income/(loss) - - (22,758) 500 - (22,258) (717) (22,975)
Total comprehensive income/(loss) for the period - - (22,758) 500 (23,146) (45,404) 865 (44,539)
Contributions by and distributions to owners
Share issue 35 12,985 - - - 13,020 - 13,020
Share issue costs recognised through equity - (2,146) - - - (2,146) - (2,146)
Cancellation of part of share premium account - (394,235) - - 394,235 - - -
Share-based payment - - - - 1,006 1,006 - 1,006
Total contributions by and distributions to owners 35 (383,396) - - 395,241 11,880 - 11,880
Changes in ownership
Acquisition of NCI - - - - (3,470) (3,470) (4,539) (8,009)
Total changes in ownership interests - - - - (3,470) (3,470) (4,539) (8,009)
Total transactions with owners of the Company 35 (383,396) - - 391,771 8,410 (4,539) 3,871
As at 30 September 2023 (audited) 739 37,428 54,952 (203) 183,489 276,405 6,212 282,617
*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserve.
Benchmark Holdings plc
Consolidated Statement of Cash Flows for the period ended 31 March 2024
All figures in £000's Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Cash flows from operating activities
Loss for the period (1,148) (2,720) (8,772) (3,399) (21,564)
Adjustments for:
Depreciation and impairment of property, plant and equipment 2,098 2,215 5,067 4,248 8,453
Depreciation and impairment of right-of-use assets 1,220 2,336 4,500 4,918 10,260
Amortisation and impairment of intangible fixed assets 4,221 4,410 8,489 9,912 18,495
(Profit)/loss on sale of property, plant and equipment (231) 1 (226) (36) (121)
Loss on sale of discontinued operation - - - - 3,774
Finance income (76) (292) (286) (320) (2,802)
Finance costs 2,710 2,028 5,395 1,715 10,535
Loss on disposal of investments in joint ventures - - (42) - -
Share of (profit)/loss of equity-accounted investees, net of tax (667) 1 (985) (55) 32
Foreign exchange gains (1,079) (1,365) (334) (1,104) (1,814)
Share-based payment expense 552 176 804 475 1,005
Tax expense 477 703 910 1,482 3,365
Decrease/(increase) in trade and other receivables 1,151 2,060 2,342 6,071 (6,570)
Decrease in inventories 1,177 946 1,747 2,517 2,877
Decrease/(increase) in biological and agricultural assets (695) (2,401) 118 893 (1,659)
(Decrease)/Increase in trade and other payables (2,564) (4,040) (15,957) (13,673) 3,909
Decrease /(increase) in provisions (1,010) (4) (1,003) (13) 386
6,136 4,054 1,767 13,631 28,561
Income taxes paid (2,513) (2,632) (3,717) (4,141) (8,556)
Net cash flows generated from operating activities 3,623 1,422 (1,950) 9,490 20,005
Investing activities
Acquisition of subsidiaries - - - - (48)
Purchase of investments in associates (143) (244) (143) (307) (558)
Receipts from disposal of subsidiaries, joint ventures, and other investments - - 37 - 1,250
Purchases of property, plant and equipment (849) (1,425) (1,770) (3,254) (5,953)
Purchase of intangibles (35) (47) (85) (77) (196)
Capitalised research and development costs (32) (143) (94) (197) (632)
Cash advances and loans made to other parties - 415 - - -
Proceeds from sale of fixed assets 253 2 271 77 227
Cash receipts from swap contracts - - - - 11
Interest received 82 159 286 319 627
Net cash flows used in investing activities (724) (1,283) (1,498) (3,439) (5,272)
Financing activities
Proceeds of share issues - - - 13,020 13,020
Share-issue costs recognised through equity - (264) - (1,650) (2,146)
Acquisition of minority interests in subsidiaries - (8,009) - (8,009) (8,009)
Proceeds from bank or other borrowings, net of borrowing fees (259) 21,402 (259) 20,802 21,847
Repayment of bank or other borrowings (860) (12,163) (1,246) (16,560) (18,470)
Interest and finance charges paid (2,257) (1,871) (4,507) (4,082) (9,131)
Repayments of lease liabilities (2,514) (2,489) (5,368) (4,689) (9,438)
Net cash used in financing activities (5,890) (3,394) (11,380) (1,168) (12,327)
Net increase/(decrease) in cash and cash equivalents (2,991) (3,255) (14,828) 4,883 2,406
Cash and cash equivalents at beginning of period 24,164 42,782 36,525 36,399 36,399
Effect of movements in exchange rate (414) (880) (938) (2,635) (2,280)
Cash and cash equivalents at end of period 20,759 38,647 20,759 38,647 36,525
Benchmark Holdings plc
Unaudited notes to the quarterly financial statements for the period ended 31
March 2024
1. Basis of preparation
Benchmark Holdings plc (the 'Company') is a company incorporated and domiciled
in the United Kingdom. These consolidated quarterly financial statements as at
and for the six months ended 31 March 2024 comprises those of the Company and
its subsidiaries (together referred to as the 'Group').
These consolidated quarterly financial statements do not comprise statutory
accounts within the meaning of section 434 of the Companies Act 2006 and are
unaudited. These financial statements do not include all the information
required for a complete set of IFRS financial statements. However, selected
explanatory notes are included to explain events and transactions that are
significant to an understanding of the changes in the Group's financial
position and performance since the last annual financial statements. The
Group's last annual statutory financial statements as at and for the year
ended 30 September 2023 were prepared in accordance with (i) UK-adopted
International Accounting Standards and (ii) IFRS adopted pursuant to
Regulation (EC) No. 1606/2002 as it applied in the European Union ("Adopted
IFRS") and are available from the Company's website at www.benchmarkplc.com
(http://www.benchmarkplc.com) .
The prior year comparatives are derived from audited financial information for
Benchmark Holdings PLC Group as set out in the Annual Report and Accounts for
the year ended 30 September 2023 and the unaudited financial information in
the Quarterly Financial Report for the six months ended 31 March 2023. The
comparative figures for the financial year ended 30 September 2023 are not the
Company's statutory accounts for that financial year. Those accounts were
approved by the Directors on 29 November 2023 and have been delivered to the
Registrar of Companies. The audit report received on those accounts was (i)
unqualified and (ii) did not contain a statement under section 498(2) or (3)
of the Companies Act 2006.
Statement of Compliance
These consolidated quarterly financial statements have been prepared and
approved by the Directors in accordance with UK and EU adopted IAS 34 'Interim
Financial Reporting'. These financial statements do not include all of the
information required for the full annual financial statements and should be
read in conjunction with the Group's last annual consolidated financial
statements as at and for the year ended 30 September 2023. These consolidated
quarterly financial statements were approved by the Board of Directors on 22
May 2024.
Going concern
The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.
As at 31 March 2024 the Group had net assets of £262.9m (30 September 2023:
£282.6m), including cash of £20.8m (30 September 2023: £36.5m) as set out
in the consolidated balance sheet. The Group made a total loss for the period
of £8.8m (year ended 30 September 2023: loss £21.6m).
As noted in the Management Report, the business experienced tough market
conditions in the shrimp markets in FY23 which continued into the first
quarter of FY24, but robust results in the second quarter are evidence of
early signs of market recovery. Additionally, the Health and Genetics business
areas both had good quarters and the group as a whole is trading in line with
expectations for the full year.
The Directors have reviewed forecasts and cash flow projections for a period
of at least 12 months including downside sensitivity assumptions in relation
to trading performance across the Group to assess the impact on the Group's
trading and cash flow forecasts and on the forecast compliance with the
covenants included within the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reduction in
medicine sales. Key downside sensitivities modelled in other areas included
assumptions on slower commercialisation of SPR shrimp, slower salmon egg sales
growth in Chile and removal of an additional financing opportunity within
Genetics, along with sensitivity of lower sales growth from a possible slower
recovery in the shrimp market in Advanced Nutrition. Mitigating measures
within the control of management have been identified should they be required
in response to these sensitivities, including reductions in areas of
discretionary spend, tight control over new hires, deferral of capital
projects and temporary hold on R&D for non-imminent products.
During the period on 26 March 2024 an additional facility of £7.5m was added
to the existing RCF with an expiry date of 31 March 2025. The original £20m
RCF term remains unaltered, ending on 27 June 2025. The Directors consider
that adequate finance facilities are in place, and with financial instruments
in place to fix interest rates and opportunities available to mitigate
globally high inflation rates, the Group continues to show resilience against
current global economic pressures.
The Board believes that the current share price materially undervalues the
combined value of Benchmark's businesses and the long-term prospects of the
Company. Consequently, the Board announced on 22 January 2024 the decision
to undertake a formal review of the Company's strategic options, which include
a potential sale of the Company as a whole or of one or more of the individual
business units. The sales process is ongoing, but there are currently no deals
identified or underway and all parts of the business are operating as usual,
so there is no impact on the Directors' assessment of going concern.
The Directors are therefore confident that even under all of the above
sensitivity analysis and ongoing strategic review, the Group has sufficient
liquidity and resources throughout the period under review whilst still
maintaining adequate headroom against the borrowing covenants. They therefore
remain confident that the Group has adequate resources to continue to meet its
liabilities as and when they fall due within the period of 12 months from the
date of approval of these financial statements. Based on their assessment, the
Directors believe it remains appropriate to prepare the financial statements
on a going concern basis.
2. Accounting policies
The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2023.
Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.
Alternative performance measures ('APMs')
The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by UK or EU-adopted
IFRS. These APMs may not be directly comparable with other companies' APMs,
and the Directors do not intend these as a substitute for, or superior to,
IFRS measures.
Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 13).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using the
prior year's foreign exchange rates.
Use of estimates and judgements
The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.
In preparing these quarterly financial statements the significant judgements
made by management in applying the Group's accounting policies and the key
sources of estimation uncertainty were the same as those applied to the
consolidated financial statements for the year ended 30 September 2023.
3. Segment information
Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.
The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:
· Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.
· Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.
· Health - the segment provides health products and services to the
global aquaculture market.
In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.
Measurement of operating segment profit or loss
Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities. This policy
was applied consistently throughout the current and prior period.
3. Segment information (continued)
Reconciliations of segmental information to IFRS measures
Segmental Revenue
All figures in £000's Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)*
Genetics 13,231 13,042 28,395 34,481 65,791
Advanced Nutrition 21,130 22,644 40,413 45,324 78,503
Health 5,401 8,692 11,460 19,077 25,514
Corporate 1,349 1,436 2,698 2,873 5,747
Inter-segment sales (1,360) (1,447) (2,742) (2,893) (5,811)
Total 39,751 44,367 80,224 98,862 169,744
Segmental Adjusted EBITDA
All figures in £000's Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)*
Genetics 3,425 3,420 5,923 5,983 14,409
Advanced Nutrition 5,276 6,169 9,876 11,466 18,374
Health 1,636 2,583 2,206 6,650 4,772
Corporate (189) (1,079) (1,183) (2,039) (3,317)
Total 10,148 11,093 16,822 22,060 34,238
Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
taxation
All figures in £000's Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)*
Total reportable segment Adjusted EBITDA 10,337 12,172 18,005 24,099 37,555
Corporate Adjusted EBITDA (189) (1,079) (1,183) (2,039) (3,317)
Adjusted EBITDA 10,148 11,093 16,822 22,060 34,238
Exceptional - restructuring, acquisition and disposal related items (1,962) (1,716) (2,479) (2,688) (7,817)
Depreciation and impairment (3,318) (4,551) (9,567) (9,166) (18,713)
Amortisation and impairment (4,221) (4,410) (8,489) (9,912) (18,495)
Net finance costs (1,317) (2,432) (4,148) (2,210) (7,412)
Loss before taxation (670) (2,016) (7,861) (1,916) (18,199)
Reconciliation of segmental information to IFRS measures - Revenue and Loss
before tax
Revenue
Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)
Total revenue per segmental information 39,751 44,367 80,224 98,862 169,744
Less: revenue from discontinued operations - (130) - (203) (268)
Consolidated revenue 39,751 44,237 80,224 98,659 169,476
Loss before tax
Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)
Profit/(loss) before tax per segmental information (670) (2,016) (7,861) (1,916) (18,199)
Less: loss before tax from discontinued operations - 279 - 732 5,505
Consolidated Profit/(loss) before tax (670) (1,737) (7,861) (1,184) (12,694)
* Results include discontinued operations, see note 5 for further detail
4. Revenue
The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2023. The Group's revenue is derived from
contracts with customers.
Disaggregation of revenue
In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).
Sale of goods and provision of services
3 months ended 31 March 2024
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 12,687 21,087 4,624 - - 38,398 - 38,398
Provision of services 542 34 777 - - 1,353 - 1,353
Inter-segment sales 2 9 - 1,349 (1,360) - - -
13,231 21,130 5,401 1,349 (1,360) 39,751 - 39,751
3 months ended 31 March 2023
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 11,083 22,635 6,115 - - 39,833 130 39,703
Provision of services 1,957 - 2,577 - - 4,534 - 4,534
Inter-segment sales 2 9 - 1,436 (1,447) - - -
13,042 22,644 8,692 1,436 (1,447) 44,367 130 44,237
6 months ended 31 March 2024
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 27,529 40,341 9,083 - - 76,953 - 76,953
Provision of services 860 34 2,377 - - 3,271 - 3,271
Inter-segment sales 6 38 - 2,698 (2,742) - - -
28,395 40,413 11,460 2,698 (2,742) 80,224 - 80,224
6 months ended 31 March 2023
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 32,204 45,307 13,564 - - 91,075 203 90,872
Provision of services 2,274 - 5,513 - - 7,787 - 7,787
Inter-segment sales 3 17 - 2,873 (2,893) - - -
34,481 45,324 19,077 2,873 (2,893) 98,862 203 98,659
12 months ended 30 September 2023
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 61,372 78,449 17,707 - - 157,528 268 157,260
Provision of services 4,409 - 7,807 - - 12,216 - 12,216
Inter-segment sales 10 54 - 5,747 (5,811) - - -
65,791 78,503 25,514 5,747 (5,811) 169,744 268 169,476
4. Revenue (continued)
Primary geographical markets
3 months ended 31 March 2024
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 6,873 138 2,348 - - 9,359 - 9,359
Vietnam - 3,071 - - - 3,071 - 3,071
India - 2,572 - - - 2,572 - 2,572
Iceland 1,478 - - - - 1,478 - 1,478
Ecuador 8 1,733 - - - 1,741 - 1,741
Canada 35 40 2,470 - - 2,545 - 2,545
Turkey - 2,317 - - - 2,317 - 2,317
Indonesia 66 853 - - - 919 - 919
Faroe Islands 1,238 - 70 - - 1,308 - 1,308
Greece - 1,711 - - - 1,711 - 1,711
China 92 743 - - - 835 - 835
United Kingdom 576 19 93 - - 688 - 688
Chile 2,009 - 420 - - 2,429 - 2,429
Rest of Europe 317 1,759 - - - 2,076 - 2,076
Rest of World 537 6,165 - - - 6,702 - 6,702
Inter-segment sales 2 9 - 1,349 (1,360) - - -
13,231 21,130 5,401 1,349 (1,360) 39,751 - 39,751
3 months ended 31 March 2023
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 6,177 252 6,157 - - 12,587 - 12,587
Vietnam - 2,330 - - - 2,330 - 2,330
India - 2,822 - - - 2,822 - 2,822
Iceland 1,184 - - - - 1,184 - 1,184
Ecuador 9 1,832 - - - 1,841 - 1,841
Canada 30 37 2,328 - - 2,395 - 2,395
Turkey - 2,528 - - - 2,528 - 2,528
Indonesia 130 418 - - - 548 - 548
Faroe Islands 2,224 - 119 - - 2,343 - 2,343
Greece - 2,002 - - - 2,002 - 2,002
China 152 1,155 - - - 1,307 - 1,307
United Kingdom 814 8 - - - 822 - 822
Chile 1,121 9 88 - - 1,218 - 1,218
Rest of Europe 474 1,716 - - - 2,190 - 2,190
Rest of World 725 7,526 - - - 8,250 130 8,120
Inter-segment sales 2 9 - 1,436 (1,447) - - -
13,042 22,644 8,692 1,436 (1,447) 44,367 130 44,237
4. Revenue (continued)
Primary geographical markets (continued)
6 months ended 31 March 2024
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 16,430 449 7,157 - - 24,036 - 24,036
Vietnam - 4,706 - - - 4,706 - 4,706
India - 6,735 - - - 6,735 - 6,735
Iceland 2,711 - - - - 2,711 - 2,711
Ecuador 40 3,222 - - - 3,262 - 3,262
Canada 95 62 2,612 - - 2,769 - 2,769
Turkey 9 4,215 - - - 4,224 - 4,224
Indonesia 158 2,135 - - - 2,293 - 2,293
Faroe Islands 2,710 - 502 - - 3,212 - 3,212
Greece - 3,659 - - - 3,659 - 3,659
China 190 1,245 - - - 1,435 - 1,435
United Kingdom 1,350 26 146 - - 1,522 - 1,522
Chile 2,993 - 1,043 - - 4,036 - 4,036
Rest of Europe 699 3,415 - - - 4,114 - 4,114
Rest of World 1,004 10,506 - - - 11,510 - 11,510
Inter-segment sales 6 38 - 2,698 (2,742) - - -
28,395 40,413 11,460 2,698 (2,742) 80,224 - 80,224
6 months ended 31 March 2023
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 23,061 342 14,452 - - 37,855 - 37,855
Vietnam - 5,025 - - - 5,025 - 5,025
India - 7,025 - - - 7,025 - 7,025
Iceland 2,972 - - - - 2,972 - 2,972
Ecuador 29 3,572 - - - 3,601 - 3,601
Canada 55 58 3,893 - - 4,006 - 4,006
Turkey 2 4,732 - - - 4,734 - 4,734
Indonesia 338 2,109 - - - 2,447 - 2,447
Faroe Islands 3,319 - 348 - - 3,667 - 3,667
Greece - 4,271 - - - 4,271 - 4,271
China 152 2,991 - - - 3,143 - 3,143
United Kingdom 1,551 27 42 - - 1,620 - 1,620
Chile 1,133 11 342 - - 1,486 - 1,486
Rest of Europe 770 3,338 - - - 4,108 - 4,108
Rest of World 1,096 11,806 - - - 12,902 203 12,699
Inter-segment sales 3 17 - 2,873 (2,893) - - -
- 34,481 45,324 19,077 2,873 (2,893) 98,862 203 98,659
4. Revenue (continued)
Primary geographical markets (continued)
12 months ended 30 September 2023
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 39,008 899 19,596 - - 59,503 - 59,503
Vietnam - 11,087 - - - 11,087 - 11,087
India - 9,743 - - - 9,743 - 9,743
Iceland 7,343 - - - - 7,343 - 7,343
Ecuador 38 7,257 - - - 7,295 - 7,295
Canada 3,071 96 4,032 - - 7,199 - 7,199
Turkey 93 7,009 - - - 7,102 - 7,102
Indonesia 637 4,099 - - - 4,736 - 4,736
Faroe Islands 6,160 - 718 - - 6,878 - 6,878
Greece - 6,759 - - - 6,759 - 6,759
China 327 4,502 - - - 4,829 - 4,829
United Kingdom 3,957 85 177 - - 4,219 - 4,219
Chile 1,824 12 991 - - 2,827 - 2,827
Rest of Europe 1,470 4,879 - - - 6,349 - 6,349
Rest of World 1,853 22,022 - - - 23,875 268 23,607
Inter-segment sales 10 54 - 5,747 (5,811) - - -
65,791 78,503 25,514 5,747 (5,811) 169,744 268 169,476
5. Discontinued activities
During FY23, the group divested its tilapia business for consideration of USD
1 in a management buy out. Consequently, these operations were classified as
discontinued in the prior year and a restatement of the consolidated income
statement for the period ended 31 March 2024 has been made to reflect these
changes.
Summary of restatement of Q2 FY23 results as reported in Q2 FY24 financial
statements
Continuing operations Discontinued operations
All figures in £000's Revenue Adjusted EBITDA Loss from continuing operations Loss from discontinued operations
As stated in Q2 FY23 financial statements 98,862 22,060 (3,399) -
Reclassified in Q1 (73) 368 453 (453)
Reclassified in Q2 (130) 194 279 (279)
As stated in Q2 FY24 financial statements 98,659 22,622 (2,667) (732)
Results from discontinued operations
Q2 FY24 Q2 FY23 YTD Q2 FY24 YTD Q2 FY23 FY23
£000 £000 £000 £000 £000
Revenue - 130 - 203 268
Cost of sales - (236) - (480) (973)
Gross profit - (106) - (277) (705)
Research and development costs - (1) - (13) (59)
Other operating costs - (87) - (272) (490)
Share of profit of equity-accounted investees, net of tax - - - - -
Adjusted EBITDA - (194) - (562) (1,254)
Exceptional loss on disposal - - - - (3,913)
EBITDA - (194) - (562) (5,167)
Depreciation and impairment - (76) - (152) (304)
Amortisation and impairment - - - - -
Operating loss / Loss before taxation - (270) - (714) (5,471)
Net finance costs - (9) - (18) (34)
Loss before taxation - (279) - (732) (5,505)
Tax on loss - - - - -
Loss from discontinued operations - (279) - (732) (5,505)
Exceptional items within discontinued operations
Q2 FY24 Q2 FY23 YTD Q2 FY24 YTD Q2 FY23 FY23
£000 £000 £000 £000 £000
Profit/(loss) on disposal of subsidiaries - - - - 3,774
Profit/(loss) on other asset disposals - - - - 139
Total exceptional recognised - - - - 3,913
Results from discontinued operations by segment
The results from discontinued operations relate solely to the Genetics
operating segment.
6. Exceptional items from continuing operations -
restructuring/acquisition and disposal related items
Items that are material because of their size or nature, are non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.
All figures in £000's Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Acquisition related items - - - 652
Exceptional restructuring costs 2,139 1,716 2,656 2,688 3,470
Disposal related items (177) - (177) - (218)
Total exceptional items 1,962 1,716 2,479 2,688 3,904
Exceptional restructuring costs in the quarter include £1,782,000 (Q2 2023:
£nil) relating to the formal review of the Company's strategic options and
potential sale of all or parts of the group, and other restructuring costs of
£357,000 (Q2 2023: £50,000). In the year to date, the costs of the
strategic review were £1,782,000 (YTD Q2 2023: £nil; FY 2023: £nil) and
other restructuring costs were £357,000 (YTD Q2 2023: £135,000; FY 2023:
£872,000). Additionally in the prior year, exceptional restructuring costs
were incurred on legal and professional expenses in relation to preparing for
listing the Group on the Oslo stock exchange, and these were £1,666,000 in Q2
2023 (YTD Q2 2023: £2,553,000; FY 2023: £2,598,000).
Disposal related items is a gain of £177,000 from sale of equipment left over
from an old business disposed of in a prior year. In FY23 there was a credit
of £235,000 for additional contingent consideration received relating to the
disposal of a subsidiary in a prior year, which was offset by £17,000 of
other disposal related costs.
In FY23 acquisition related items comprise fees incurred in the year in
connection with an aborted acquisition.
7. Net finance costs from continuing operations
All figures in £000's Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Interest received on bank deposits 76 163 286 323 627
Foreign exchange gains on financing activities - - - - 158
Foreign exchange gains on operating activities 1,808 499 2,063 5,169 4,709
Cash flow hedges - ineffective portion of changes in fair value - 129 - 2,651 2,176
Finance income 1,884 791 2,349 8,143 7,670
Leases (interest portion) (353) (527) (689) (873) (1,620)
Foreign exchange losses on operating activities (491) (1,195) (1,102) (5,961) (4,547)
Interest expense on financial liabilities measured at amortised cost (2,357) (1,491) (4,706) (3,501) (8,881)
Finance costs (3,201) (3,214) (6,497) (10,335) (15,048)
Net finance costs recognised in profit or loss (1,317) (2,423) (4,148) (2,192) (7,378)
8. Taxation
All figures in £000's Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Analysis of charge in period
Current tax:
Current income tax expense on profits for the period 1,307 997 2,626 2,835 6,178
Adjustment in respect of prior periods - - - - (880)
Total current tax charge 1,307 997 2,626 2,835 5,298
Deferred tax:
Origination and reversal of temporary differences (830) (293) (1,716) (1,352) (1,933)
Total deferred tax charge/(credit) (830) (293) (1,716) (1,352) (1,933)
- -
Total tax charge 477 704 910 1,483 3,365
9. Loss per share
Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.
Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Loss attributable to equity holders of the parent (£000)
Continuing operations (1,321) (2,579) (8,948) (3,409) (17,641)
Discontinued operations - (279) - (732) (5,505)
Total (1,321) (2,858) (8,948) (4,141) (23,146)
Weighted average number of shares in issue (thousands) 739,464 723,173 739,480 724,505 731,935
Basic loss per share (pence)
Continuing operations (0.18) (0.36) (1.21) (0.47) (2.41)
Discontinued operations - (0.04) - (0.10) (0.75)
Total (0.18) (0.40) (1.21) (0.57) (3.16)
Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.
Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.
A total of 14,056,643 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (30 September
2023: 8,948,132 and 31 March 2023: 4,312,880). These potential ordinary shares
could dilute earnings/loss per share in the future.
10. Assets held for sale
During 2022, management committed to sell certain property, plant and
equipment held within the Health business area. The property concerned is no
longer required by the business and the decision was made to sell. The market
value of the property fell during the period and a further impairment charge
of £200,000 has been incurred to write the asset down to its current market
value of £300,000 (30 September 2023: £850,000). The property was sold for
£300,000 on 28 March 2024.
There were no liabilities directly associated with the assets held for sale.
Assets held for sale YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
(unaudited)
(audited)
All figures in £000's
Property, plant and equipment - - 850
Total Assets held for sale - - 850
11. Loans and borrowings
YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
(unaudited)
(audited)
All figures in £000's
Non-Current
2025 750m NOK Loan notes 54,914 56,756 57,604
Bank borrowings 14,808 16,974 16,799
Unamortised debt issue costs (373) - (742)
Lease liabilities 6,863 9,148 8,293
76,212 82,878 81,954
Current
Bank borrowings 9,257 9,421 9,320
Unamortised debt issue costs (1,048) - (842)
Lease liabilities 9,083 12,694 11,567
17,292 22,115 20,045
Total loans and borrowings 93,504 104,993 101,999
The Group has an unsecured floating rate listed green bond of NOK 750m in
issue. The bond which matures in September 2025, has a coupon of three-month
NIBOR + 6.50% p.a. with quarterly interest payments, and is listed on the Oslo
Stock Exchange.
The Group has a secured GBP 20m RCF provided by DNB Bank ASA, maturing on 27
June 2025. This facility was extended on the same terms in March 2024 by GBP
7.5m, to a total facility of GBP 27.5m, with the GBP 7.5m extension maturing
on 27 March 2025. The margin on this combined facility is a minimum of 2.75%
and a maximum of 3.25%, dependent upon the leverage of the Group above the
relevant risk-free reference or IBOR rates depending on which currency is
drawn. As at 31 March 2024 there was £19.75m undrawn.
Additionally, Benchmark Genetics Salten AS had the following loans (which are
ring-fenced debt without recourse to the remainder of the Group) at 31 March
2024:
• term loan with Nordea Bank with a balance of NOK 164.3m, which
has a maturity date of five years ending 15 January 2028 and an interest rate
of 2.5% above three-month NIBOR.
• twelve month working capital facility of NOK 20.0m provided by
Nordea Bank Norge Abp. This was undrawn at 31 March 2024
• term loan with a balance of NOK 33.2m provided by Innovasjon
Norge. The loan is a 12-and-a-half year term loan maturing in March 2031. The
interest rate on this loan at 31 March 2024 was 7.45%
• an additional 15-year term loan with a balance of NOK 9.7m
provided by Innovasjon Norge and maturing in July 2038. The interest rate on
this loan at 31 March 2024 was 6.6%
• a loan of NOK 15.5m provided by the minority shareholder Salten
Stamfisk AS. The loan attracts interest at 2.5% above three month NIBOR and is
repayable on maturity of the Nordea loan above.
12. Share capital and additional paid-in share capital
Number Share Capital Additional paid-in
share capital
Allotted, called up and fully paid £000 £000
Ordinary shares of 0.1 pence each
Balance at 30 September 2023 739,352,390 739 37,428
Exercise of share options 199,580 - -
Shares issued through placing and open offer 34,576 - -
Balance at 31 March 2024 739,586,546 739 37,428
13. Alternative performance measures and other metrics
Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.
Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
and is shown on the Income Statement.
Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.
Adjusted Operating Profit is operating loss before exceptional items and
amortisation and impairment of intangible assets excluding development costs
as reconciled below.
Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items as
reconciled below. These measures are not defined performance measures in IFRS.
The Group's definition of these measures may not be comparable with similarly
titled performance measures and disclosures by other entities.
13. Alternative performance measures and other metrics (continued)
Reconciliation of Adjusted Operating Profit/(loss) to Operating Profit/(loss)
All figures in £000's Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Revenue 39,751 44,237 80,224 98,659 169,476
Cost of sales (18,866) (19,313) (40,976) (49,337) (82,726)
Gross profit 20,885 24,924 39,248 49,322 86,750
Research and development costs (1,542) (1,434) (3,059) (2,985) (6,069)
Other operating costs (9,862) (12,203) (20,352) (23,771) (45,157)
Depreciation and impairment (3,318) (4,475) (9,567) (9,014) (18,409)
Amortisation of capitalised development costs (604) (610) (1,211) (1,227) (2,437)
Share of profit/(loss) of equity accounted investees net of tax 667 - 985 56 (32)
Adjusted operating profit 6,226 6,202 6,044 12,381 14,646
Exceptional - restructuring, acquisition and disposal related items (1,962) (1,716) (2,479) (2,688) (3,904)
Amortisation and impairment of intangible assets excluding development costs (3,617) (3,800) (7,278) (8,685) (16,058)
Operating profit/(loss) 647 686 (3,713) 1,008 (5,316)
Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax
All figures in £000's Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Loss before taxation (670) (1,737) (7,861) (1,184) (12,694)
Exceptional - restructuring, acquisition and disposal related items 1,962 1,716 2,479 2,688 3,904
Amortisation and impairment of intangible assets excluding development costs 3,617 3,800 7,278 8,685 16,058
Adjusted profit before tax 4,909 3,779 1,896 10,189 7,268
Other Metrics
All figures in £000's Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Total R&D Investment
Research and development costs
- Continuing operations 1,542 1,434 3,059 2,985 6,069
- Discontinued operations - 1 - 13 59
Internal capitalised development costs 32 144 94 197 632
Total R&D investment 1,574 1,579 3,153 3,195 6,760
All figures in £000's Q2 2024 Q2 2023 YTD Q2 2024 YTD Q2 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Adjusted EBITDA excluding fair value movement in biological assets
Adjusted EBITDA 10,148 11,287 16,822 22,622 35,492
Exclude fair value movement (287) (1,401) 506 (247) 103
Adjusted EBITDA excluding fair value movement in biological assets 9,861 9,886 17,328 22,375 35,595
13. Alternative performance measures and other metrics (continued)
Liquidity
A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.
All figures in £000's Q2 2024 Q2 2023 FY 2023
(unaudited)
(unaudited)
(audited)
Cash and cash equivalents 20,759 38,647 36,525
Undrawn bank facility 19,750 12,110 12,250
Total liquidity 40,509 50,757 48,775
The undrawn bank facility relates to the RCF facility. At 31 March 2024,
£7.75m of the RCF was drawn (31 March 2023: £7.89m, 30 September 2023:
£7.75m), leaving £19.75m undrawn (31 March 2023: £12.11m, 30 September
2023: £12.25m).
14. Net debt
Net debt is cash and cash equivalents less loans and borrowings.
31 March 2024 31 March 2023 30 September 2023
All figures in £000's (unaudited) (unaudited) (audited)
Cash and cash equivalents 20,759 38,647 36,525
Loans and borrowings (excluding lease liabilities) - current (8,209) (9,421) (8,478)
Loans and borrowings (excluding lease liabilities) - non-current (69,349) (73,730) (73,661)
Net debt excluding lease liabilities (56,799) (44,504) (45,614)
Lease liabilities - current (9,083) (12,694) (11,567)
Lease liabilities - non-current (6,863) (9,148) (8,293)
Net debt (72,745) (66,346) (65,474)
We hereby confirm that the financial statements for the period from 1 October
2023 to 31 March 2024, to the best of our knowledge, have been prepared in
accordance with IAS 34 - Interim Financial Reporting - and that the
information in the accounts gives a true and fair view of the Group and of the
Group's assets, liabilities, financial position and overall results.
We also confirm that, to the best of our knowledge, the half-year report gives
a true and fair view of the main events during the accounting period and their
effect on the accounts for the second half year, as well as the principal
risks and uncertainties, described below (which have remained unchanged from
those disclosed in the Company Annual Report of FY23), facing the Company and
the Group in the next accounting period.
This Statement was approved by the board of directors and signed on its behalf
by:
Trond Williksen
(Chief Executive Officer)
Date: 22 May 2024
Principal risks and uncertainties
The Group's principal risks are categorised as either strategic, operational,
financial or emerging risks and are developed through the Audit Committee and
Board's review of the Group's risk register, performance of our businesses and
analysis of emerging global trends.
Strategic risks
Risks Risk commentary Risk mitigation and controls Business Areas affected
Competition and loss of competitive advantage · Falling behind competitors with the development and · Innovative development focus and strong pipeline of products. Advanced Nutrition, Health and Genetics
commercialisation of new, innovative products.
· Intellectual Property ("IP") protection including patents.
· Threat to market share and revenues.
· Strong customer relationships with key account structure.
Reliance on continued success of existing products · The Group is currently exposed · Increasing number of products/ services from development pipeline Advanced Nutrition, Health and Genetics
to risk by limited diversity of revenue streams. is diversifying revenues.
· Risks associated with legal costs of protecting Group IP. · Strong Group legal team with dedicated IP expertise.
· Group products require the holding of certain licences, · Vigorous defence of own IP.
accreditations or regulatory approvals that could be withdrawn.
· High levels of employee competency and stringent processes
· Failure to gain additional claims on the labels for certain Group related to
products which could result in reduced revenue from such products.
regulatory affairs.
· Failure to achieve the projected · Highly proficient and experienced
customers growth/uptake for newly commercial team equipped with
launched products extensive knowledge and with robust
customer relationships.
Delivery of cross-Group synergies · Risks associated with failure to fully realise operational · EMT continues tracking progress of the Group strategy on a weekly Advanced Nutrition, Health and Genetics
synergies and cost benefits. basis.
· Lower profitability and cash generation, and slower returns than · Extended-EMT assists with planning and managing
anticipated.
key projects.
· Risks on delivering the synergy within the timeline set.
New product · Risk that pipeline products may · Close dialogue with regulators. Advanced Nutrition, Health and Genetics
and service commercialisation
be delayed or fail technically
before launch. · The innovation board (which includes the head of Group
Innovation) monitors the R&D projects across the Group.
· Risk inherent in timing and market penetration of new products
and services. · Experienced Group regulatory affairs team, commercial team and
Marketing team.
· Close dialogue with customers regarding their product and service
satisfaction to enable efficient and appropriate reaction to their feedback
and needs.
Operational risks
Risks Risk commentary Risk mitigation and controls Business Areas affected
Environmental risk and crisis management · The nature of certain of the Group's operating activities exposes · We have implemented standards and requirements which govern key Advanced Nutrition, Health and Genetics
us to certain significant risks to the environment, such as incidents risk management activities such as inspection, maintenance, testing, business
associated with releases of chemicals or hazardous substances when conducting continuity and crisis response.
our operations, which could result in liability, fines, risk to our product
permissions and reputational damage.
· There is a risk that natural disasters could lead to damage to
infrastructure, loss of resources, products or containment of hazardous
substances.
· Our business activities could be disrupted if we do not respond,
or are perceived not to respond, in an appropriate manner to any major crisis
or if we are not able to restore or replace critical operational capacity.
Biological and climatic risks · The Group is exposed to the risk of disease within the Group's · The Group operates the highest levels of biosecurity. Advanced Nutrition, Health and Genetics
own operations and disease in the market resulting in possible border
closures. · The Group holds genetic stock at multiple sites; increasingly
sources from its own land-based salmon breeding facilities.
· Sales of the Group's sea lice medicines and other relevant
solutions such as CleanTreat® are affected by the degree of sea lice · The Group operates containment zones which mitigates the risk of
challenge in the environment, which is driven by sea temperatures and other border closures affecting its ability to import or export.
biological factors.
· The Group has placed increased focus on insuring its biological
stock.
· The Group's product diversity across business areas offers some
mitigation.
Volatility of end markets (salmon, sea bass and shrimp markets) and market and · Market fluctuations in shrimp production volumes and pricing, · The geographic diversity of the business area's customer base Advanced Nutrition, Health and Genetics
regulatory trends often influenced by disease, drive customer and food services demand for offers some mitigation.
shrimp.
· The Group's product diversity across business areas offers some
· Market and regulatory trends for tackling sea lice have an mitigation.
influence on customer demand for the Group's sea lice products.
Threats to the supply chain · Benchmark is reliant on a small number of key raw materials and · Dual supplies of raw materials where possible. Advanced Nutrition, Genetics, Health
manufacturers and suppliers for important products.
· Supplies secured with contractual arrangements, and import
· The Group has R&D and production sites which are important to its authorisations in the process of being applied for where deemed material for
current revenues and future success and which are leased. the Group.
· Commissioning of new facilities could be delayed leading to late · Seek long-term tenure of sites.
product deliveries.
· Benchmark relies on third parties for importation authorisations
required in certain jurisdictions for certain products.
Health and well-being of employees · Poor health or well-being impacts employees' lives and reduces · Well-developed health and safety management regime in place across the Advanced Nutrition, Genetics, Health
productivity. Group.
· Some aquaculture activities have inherent operational risks. · Senior level commitment to ESG programme Group-wide.
Recruitment and retention of high-calibre people · To maintain market leadership, it is essential that the Group has and · Centralised people team delivering people strategy. Advanced Nutrition, Genetics, Health
keeps people with key skills.
· Succession planning process.
· Remuneration policy designed to encourage retention.
Loss of key IT system · The Group IT systems facilitate daily work, collaboration and hold · Internal experienced IT team. Advanced Nutrition, Genetics, Health
Group IP and trade secrets.
· Increasing integration of software platforms to improve security and
· Multiple risks of systems failure or cyber attack. reliability.
· Loss of access or key information would be disruptive to the Group. · The Group increased the frequency of phishing simulation exercises to
ensure staff awareness of cyber security.
Geopolitical risk · The diverse locations of our operations around the world expose us to a · We seek to manage this risk through development and maintenance of Advanced Nutrition, Genetics, Health
wide range of political developments and consequent changes to the economic relationships with governments and stakeholders. We closely monitor events and
and operating environment. Geopolitical risk is inherent to many regions in implement risk mitigation plans where appropriate.
which we operate, and heightened political or social tensions or changes in
key relationships could adversely affect the Group.
Application of appropriate standards of governance · As an international business, the Group is required to comply with laws · Experienced Group legal, finance, people, regulatory affairs, investor Advanced Nutrition, Genetics, Health
and regulations in several jurisdictions. relations, health and safety and IT teams work closely with the business
areas.
· There is risk of non-compliance leading to potential fines, penalties,
loss of revenues and damage to reputation. · Training programme, whistleblowing policy, and informal routes by which
concerns can be raised, are designed to identify and address potential
non-compliance.
Financial and legal risks
Risks Risk Risk mitigation Business Areas affected
commentary
and controls
Maintain liquidity and manage leverage · Failure to identify and maintain sufficient liquidity headroom. · Close control of cash flows with regular update of short- and Advanced Nutrition, Genetics, Health
long-term projections.
· Risk to funding of key growth strategies.
· The refinanced facilities provide greater covenant flexibility
and headroom.
· Group Treasury Manager oversees cash flow management.
· Group treasury policy introduced to support how the Group manages
cash.
Growth in trading results in higher investment in working capital · Top-line growth through new products and markets can drive · Business area management of pricing and credit terms. Advanced Nutrition, Genetics, Health
changing patterns of working capital.
· Close monitoring of investment in working capital by the EMT and
· Growth in some markets presents increased risk of slow paying or Plc Board.
bad debts.
· Key performance indicators include working capital measures.
Currency exchange · The Group as a whole is also exposed to fluctuations in currency · The Group reduces its exposure to its principal foreign currency Advanced Nutrition, Genetics, Health
exchange rates. These impact sales volumes where products are priced by risks through the use of hedging instruments.
reference to USD but sold in local currencies; and impacts reported results
when local results, assets and liabilities are converted to GBP for reporting · Group treasury policy explains how the Group should manage FX
purposes. risk.
Criminal activity, fraud, bribery and compliance risk · Some countries where the Group operates may be exposed to high · The Group provides compliance training programmes to all its Advanced Nutrition, Genetics, Health
levels of risk relating to criminal activity, fraud, bribery and corruption. employees through an online training platform and provide face-to-face and
virtual training to higher risk teams.
· There are a number of regulatory requirements applicable to the
Group and its listing on the London and Oslo Stock exchanges. · The Group has introduced a code of conduct for its suppliers.
· The CFO and Group Legal Counsel are involved in mitigating
fraudulent activities in the Group.
· The Group has access to competent
and experienced external counsel.
· Fraud response policy introduced.
Emerging risks
Risks Risk Risk mitigation Business Areas affected
commentary
and controls
Climate change · Climate change and the evolving regulatory environment may expose · The Group's Sustainability Committee reports to the Board Advanced Nutrition, Genetics, Health
the Group to regulatory breaches, significant disruption, reputational risk or regularly and its mandate is to ensure the Group's strategy and operations are
a reduction in supply for biological raw materials, and demand for products or carried out within the framework of caring for the environment, people, and
services. animals. Its work aligns with major frameworks including the London Stock
Exchange Guidance for Environmental, Social and Governance reporting and the
UN Sustainable Development Goals.
· New ESG strategy approved and implemented by the Group.
· Plan adopted for reduction in the Group's carbon emissions and
progressing according to timetable set.
· The Group is exploring alternatives
solutions to decrease its reliance
on raw materials that could be
vulnerable to the impacts of climate
changes.
Environmental, Social and Governance responsibilities · Increasingly our stakeholders are requiring reassurance that we · Code of Conduct in place. Advanced Nutrition, Genetics, Health
are overseeing and responding to ethical and environmental issues across the
Group's business. · New ESG strategy approved and in place.
· Plan adopted for reduction in the Group's carbon emissions.
· Code of conduct and ABC policies in place.
· Green bond successfully launched and subscribed.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IR SESESFELSELI